The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - Selecta released Q2 2018 results and announced updates regarding their Phase 2 SEL-212 5+0 dosing and Phase 3 plans. Here are main takeaways: 5+0 dosing to be … Continue Reading
Read nowInsights - The pediatric committee at the European Medicines Agency (EMA) held discussions last week on Fennec’s STS, which is nearing a MAA submission sometime in Q4. The title … Continue Reading
PremiumInsights - Our original thesis was that GBT would show a clear improvement in at least 1 of 2 secondary events (in addition to the primary Hb … Continue Reading
PremiumInsights - GBT announced their highly anticipated Phase 3 Part A data this morning and a lot was left to be desired. The data that was presented was good, … Continue Reading
Read nowInsights - Fennec (FENC) announced that their Phase 3 results, initially released back in October 2017 (read  more), were published in the June 21, 2018 issue of the New … Continue Reading
Read nowInsights - Selecta announced updated data on their 3+2 dosing for Phase 2 this morning. This data is not all that relevant because the company has said … Continue Reading
Read nowInsights - GBT released their EHA poster for sickle cell disease adolescent patients this morning. The stock is trading down more than 10% on this release, presumably … Continue Reading
Premium
